Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337602 | 0.88 | CYP11B1 (0.55) | DYRK1BMKNK1MKNK2DYRK1AMEN1 | |
| SCHEMBL29521950 | 0.85 | MAOA (0.72) | MAOAMKNK1MKNK2MEN1PSIP1 | |
| SCHEMBL18745741 | 0.84 | HSD17B10 (0.65) | MAOAMKNK1MKNK2ATMMEN1 | |
| SCHEMBL27993963 | 0.83 | MAOA (0.52) | DYRK1BMAOAMKNK1MKNK2MEN1 | |
| SCHEMBL21692173 | 0.83 | ATM (0.62) | MKNK1MKNK2ATMCYP3A4CYP11B1 | |
| SCHEMBL722248 | 0.83 | ATM (0.62) | MKNK1MKNK2ATMCYP3A4CYP11B1 | |
| SCHEMBL6754399 | 0.83 | MKNK1 (0.71) | DYRK1BMKNK1MKNK2DYRK1AMEN1 | |
| SCHEMBL30268308 | 0.83 | MKNK1 (0.71) | DYRK1BMKNK1MKNK2DYRK1AMEN1 | |
| SCHEMBL4152091 | 0.82 | NTRK1 (0.55) | DYRK1BMKNK1MKNK2DYRK1AMEN1 | |
| Hydrochloric Acid SCHEMBL6756841 | 0.81 | MKNK1 (0.69) | DYRK1BMKNK1MKNK2DYRK1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974067-A | High-thermal-conductivity graphite film of pyridine ring modified polyimide and preparation method thereof | 富优特(山东)新材料科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| WO-2021117846-A1 | COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION | 日本新薬株式会社 | 2021-06-17 | — | — | WO | claimed |
| EP-4638445-A1 | 1,2,4-THIAZOLIDIN-3-ONE-1,1-DIOXIDE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-05-08 | — | — | US | disclosed |
| CN-119874668-A | Main protease regulator and application thereof | 北京昌平实验室 | 2025-04-25 | — | — | CN | disclosed |
| CN-118946360-A | Bicyclic heteroarenes and methods of use thereof | 奇尼塔公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4444317-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240228476-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4395499-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| EP-4395521-A1 | CONDENSED CYCLIC COMPOUND, LIGHT-EMITTING DEVICE COMPRISING THE CONDENSED CYCLIC COMPOUND, AND ELECTRONIC APPARATUS COMPRISING THE LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024137727-A1 | 1,2,4-THIAZOLIDIN-3-ONE-1,1-DIOXIDE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| US-7390798-B2 | Carboxamide spirolactam CGRP receptor antagonists | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390798-B2 | Carboxamide spirolactam CGRP receptor antagonists | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-7288559-B2 | Carboxamide spirohydantoin CGRP receptor antagonists | MERCK + CO, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288559-B2 | Carboxamide spirohydantoin CGRP receptor antagonists | MERCK + CO, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070111982-A1 | Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides | MERCK SHARP & DOHME LLC | 2007-05-17 | — | — | US | disclosed |
| US-20070111982-A1 | Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides | MERCK SHARP & DOHME LLC | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228476-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPN2, PTPN22, PTPN1 | DYRK1B 222/4885MAOA 1918/4885MKNK1 544/4885 |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | DYRK1B 4231/4885MAOA 795/4885MKNK1 2508/4885 |
| US-20070111982-A1 | Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides | CALCA, CALCRL, CALCB | DYRK1B 4581/4885MAOA 1467/4885MKNK1 2987/4885 |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | TARDBP, TDP2, PSEN2 | DYRK1B 1877/4885MAOA 180/4885MKNK1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.